In-licensing: NCE's – New Formulation Projects Indicated For Inflammation/autoimmune Disorders

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

In-licensing
View

NCE's – New formulation projects indicated for inflammation/autoimmune disorders

Palau Pharma is seeking new formulation projects with novel DDT

Full description

Palau Pharma is seeking new formulation projects with novel DDT and combination products, that are indicated for inflammation or autoimmune disorders. The company would prefer drugs to be orally delivered but would consider topical or transdermal delivery as well.

These drugs should have strong patent protection and can be developed from the pre-clinical stage through to the Phase III stage.

Development status

Phase I/II

Type of business relationship sought

Licensing or acquisition.

Licensing contact

Heidi Sisniega
Head
Business Development & Licensing

Contact directly

Company details

Palau Pharma

PALAU PHARMA is a product-driven specialty pharmaceutical company devoted to the discovery and development of safer medicines for the treatment of inflammatory and autoimmune conditions.

View profile

Visit website

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

NCEs, new patented formulations and products

Biologic Entities in clinical development, registered, novel or bio-generic/follow on.

Esmolol, Cyclosporine, Ketoprofen & Tramadol injections

Acquisition of established pharmaceuticals in the UK / Irish market

Related categories

Industry sector: Drug discovery
Therapeutic target: Immune related disorders / Autoimmune disease (non-specific); Immune related disorders / Immune disorder (non-specific); Immune related disorders; Musculoskeletal / Muscular / Inflammation

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us